KEXING BIOPHARM CO.(SH:688136) Zheng Quan Ri Bao·2025-10-29 23:07Core Viewpoint - The company emphasizes the accuracy and completeness of its quarterly report, ensuring no false statements or omissions exist, and holds legal responsibility for the report's content [2][3]. Financial Data - The financial statements for the third quarter are unaudited, covering the period from the beginning to the end of the quarter [3][6]. - The report includes major accounting data and financial indicators, but specific figures are not provided in the text [3][6]. - The company reported no net profit from mergers under common control for the current and previous periods [6]. Shareholder Information - The total number of ordinary shareholders and the top ten shareholders' holdings are disclosed, with "Kexing Biological Pharmaceutical Co., Ltd. Repurchase Special Securities Account" holding 3,149,905 shares, representing 1.57% of the total [4][6]. Other Important Information - There are no significant changes in the shareholding structure or other operational reminders for the reporting period [5][6].